Agilent Technologies Inc. (A) exhibits 52.4% gross margins and 15.3% return on invested capital within Health Care (Biotechnology: Laboratory Analytical Instruments), balanced against a 28.4x enterprise multiple and 6.6% implied options volatility.
Sustained 52.4% gross profitability converts into 21.3% operating margin and 15.3% ROIC, outpacing sector cost of capital.
ROIC: 15.3% // GM: 52.4%YoY revenue trajectory of +6.7% paired with 2.26% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +6.7% // FCF YLD: 2.26%Altman Z-Score of 6.50 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 6.50 // F-SCORE: 9/9Trading at 39.2x trailing P/E (36.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 39.2x // EV/EBITDA: 28.4xOptions market prices a ±6.6% implied move with a 0.75 put/call ratio around $178.00 max pain.
IMPL MOVE: ±6.6% // P/C: 0.75Elevated industry capital intensity and customer concentration in Biotechnology: Laboratory Analytical Instruments require continuous execution to defend 18.8% net margins.
NET MARGIN: 18.8% // D/E: 0.36x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for A & activate live FRED threshold breach alerts.